Roche has extended its partnership with the World Federation of Hemophilia (WFH) to expand access to treatments for hemophilia through the end of 2028, the company announced. Under the partnership, Roche will continue to provide its prophylactic (preventive) treatment for hemophilia A to the WFH’s Humanitarian…
News
A blood test to determine the amount of active factor IX — the clotting factor that is missing in hemophilia B — in patients ages 2 and older is now available in clinical labs in Canada, the European Union, Australia, and New Zealand. The test, called CRYOcheck Chromogenic…
Treatment with abatacept, a medication approved for rheumatoid arthritis, prevented the formation of inhibitors against hemophilia A replacement therapies in a rat model, a study demonstrates. These findings support the use of abatacept to prevent immune responses against human proteins in a preclinical setting, the researchers noted. The study,…
The U.S. Food and Drug Administration (FDA) has lifted a clinical hold on the Phase 3 trial testing the safety and effectiveness of SB-525 (giroctocogene fitelparvovec), an experimental gene therapy for hemophilia A. Pfizer, which is developing the therapy along with Sangamo Therapeutics, expects to begin dosing…
A Russian military plane crash near Tetiana Zamorska’s home in Kyiv, Ukraine, was a sign that it was time for her and her family to leave. The treacherous, 34-hour pilgrimage that ultimately brought the group of eight by car to temporary accommodations in neighboring Poland last month was physically and emotionally difficult,…
Eptacog beta was safe and almost 100% effective at stopping bleeds within 24 hours in boys ages 12 and younger with hemophilia A or B, according to final data from the Phase 3 PERSEPT 2 trial. According to researchers, this bypass agent may be an important option for…
The rate of intracranial hemorrhage (ICH) — a bleed in the brain — is higher in children and adults with hemophilia than in the general population, an Italian study suggests. ICH rates were particularly high among adults with mild disease and with high blood pressure. Most patients received only…
CSL Behring will donate 500 million international units (IUs) of coagulation factor therapy to the World Federation of Hemophilia (WFH) in an effort to promote reliable access to treatment for bleeding disorders, including hemophilia, across more than 60 developing countries. The donation marks the fifth multiyear…
Believe Limited, continuing a partnership with BioMarin Pharmaceutical and working with the Foundation for Art & Healing, announced plans to produce a documentary film on the everyday challenges and victories of living with a bleeding disorder. The digital content production company, again with the support of BioMarin, produced “…
Factor VIII (FVIII) levels in the bloodstream of men with severe hemophilia A treated with the investigational gene therapy Roctavian appear to be influenced by regulatory molecules involved in F8 gene activity and FVIII protein folding and release, a study reveals. Researchers also found a dose-dependent relationship between…
Recent Posts
- Growing up before treatments for hemophilia were safe, part 3
- Early prophylaxis tied to less joint damage in severe hemophilia A
- I tell my son, ‘When you’re eating an elephant, take it one bite at a time’
- Holding space for grief and love in the hemophilia community
- Hand swelling is first sign of aquired hemophilia A for new mom: Report